This could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from 
LLY and Farxiga from 
AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out commercialization and sales at the end of June. This should be a fun ride! This is my own opinion and should not be taken as financial advice. Own your own trades.
LLY and Farxiga from AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out commercialization and sales at the end of June. This should be a fun ride! This is my own opinion and should not be taken as financial advice. Own your own trades.
Exención de responsabilidad
La información y las publicaciones no pretenden ser, ni constituyen, asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones no pretenden ser, ni constituyen, asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.